Lipoprotein lipase and PPAR alpha gene polymorphisms, increased very-low-density lipoprotein levels, and decreased high-density lipoprotein levels as risk markers for the development of visceral leishmaniasis by leishmania infantum

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Carvalho, Márcia Dias Teixeira ^a   Alonso, Diego Peres ^b   Vendrame, Célia Maria Vieira ^a   Costa, Dorcas Lamounier ^c   Costa, Carlos Henrique Nery ^c   Werneck, Guilherme Loureiro ^d,e   Ribolla, Paulo Eduardo Martins ^b   Goto, Hiro ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

^d STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN; LEUCINE; LIPOPROTEIN LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE; VERY LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE PREDISPOSITION; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LEISHMANIA INFANTUM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; VISCERAL LEISHMANIASIS; YOUNG ADULT; BLOOD; GENETICS;

LEISHMANIA INFANTUM;

GENOTYPE; HUMANS; LEISHMANIASIS, VISCERAL; LIPOPROTEIN LIPASE; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; POLYMORPHISM, GENETIC; PPAR ALPHA; TRIGLYCERIDES;

EID: 84932163892     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/230129     Document Type: Article

References (46)

1. I. L. Mauricio, M. W. Gaunt, J. R. Stothard, and M. A. Miles, "Genetic typing and phylogeny of the Leishmania donovani complex by restriction analysis of PCR amplified gp63 intergenic regions," Parasitology, vol. 122, no. 4, pp. 393-403, 2001.
2. R. Badaro, T. C. Jones, R. Lorenco et al., "A prospective study of visceral leishmaniasis in an endemic area of Brazil," Journal of Infectious Diseases, vol. 154, no. 4, pp. 639-649, 1986.
3. H. Goto and M. D. G. Prianti, "Immunoactivation and immunopathogeny during active visceral leishmaniasis," Revista do Instituto de Medicina Tropical de Sao Paulo, vol. 51, no. 5, pp. 241-246, 2009.
4. B. Bucheton, L. Abel, M. M. Kheir et al., "Genetic control of visceral leishmaniasis in a Sudanese population: candidate gene testing indicates a linkage to the NRAMP1 region," Genes & Immunity, vol. 4, no. 2, pp. 104-109, 2003.
5. H. S. Mohamed, M. E. Ibrahim, E. N. Miller et al., "SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in the Sudan," European Journal of Human Genetics, vol. 12, no. 1, pp. 66-74, 2004.
6. H. S. Mohamed, M. E. Ibrahim, E. N. Miller et al., "Genetic susceptibility to visceral leishmaniasis in The Sudan: linkage and association with IL4 and IFNGR1," Genes and Immunity, vol. 4, no. 5, pp. 351-355, 2003.
7. T. M. Karplus, S. M. B. Jeronimo, H. Chang et al., "Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection," Infection and Immunity, vol. 70, no. 12, pp. 6919-6925, 2002.
8. B. Bucheton, L. Abel, S. El-Safi et al., "A major susceptibility locus on chromosome 22q12 plays a critical role in the control of kala-Azar," American Journal of Human Genetics, vol. 73, no. 5, pp. 1052-1060, 2003.
9. B. Bucheton, L. Argiro, C. Chevillard et al., "Identification of a novel G245R polymorphism in the IL-2 receptor membrane proximal domain associated with human visceral leishmaniasis," Genes and Immunity, vol. 8, no. 1, pp. 79-83, 2007.
10. A. Moravej, M. Rasouli, S. Asaei, M. Kalani, and Y. Mansoori, "Association of interleukin-18 gene variants with susceptibility to visceral leishmaniasis in Iranian population," Molecular Biology Reports, vol. 40, no. 6, pp. 4009-4014, 2013.
11. A. Moravej, M. Rasouli, M. Kalani et al., "IL-1 (-511T/C) gene polymorphism not IL-1 (+3953T/C) and LT- (+252A/G) gene variants confers susceptibility to visceral leishmaniasis," Molecular Biology Reports, vol. 39, no. 6, pp. 6907-6914, 2012.
12. J. M. Blackwell, M. Fakiola, M. E. Ibrahim et al., "Genetics and visceral leishmaniasis: Of mice and man," Parasite Immunology, vol. 31, no. 5, pp. 254-266, 2009.
13. M. Hajilooi, K. Sardarian, M. Dadmanesh et al., "Is the IL-10-819 polymorphism associated with visceral leishmaniasis?" Inflammation, pp. 1-6, 2013.
14. S. Mehrotra, M. Fakiola, J. Oommen et al., "Genetic and functional evaluation of the role of CXCR1 and CXCR2 in susceptibility to visceral leishmaniasis in North-East India," BMC Medical Genetics, vol. 12, article 162, 2011.
15. S. Mehrotra, M. Fakiola, A. Mishra et al., "Genetic and functional evaluation of the role of DLL1 in susceptibility to visceral leishmaniasis in India," Infection, Genetics and Evolution, vol. 12, no. 6, pp. 1195-1201, 2012.
16. S. Mehrotra, J. Oommen, A. Mishra et al., "No evidence for association between SLC11A1 and visceral leishmaniasis in India," BMC Medical Genetics, vol. 12, article 71, 2011.
17. M. Fakiola, A. Strange, H. J. Cordell et al., "Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis," Nature Genetics, vol. 45, no. 2, pp. 208-213, 2013.
18. C. R.Davies andA. S.M.Gavgani, "Age, acquired immunity and the risk of visceral leishmaniasis: a prospective study in Iran," Parasitology, vol. 119, no. 3, pp. 247-257, 1999.
19. E. D. Bekaert, E. Dole, D. Y. Dubois et al., "Alterations in lipoprotein density classes in infantile visceral Leishmaniasis: presence of apolipoprotein SAA," European Journal of Clinical Investigation, vol. 22, no. 3, pp. 190-199, 1992.
20. E. D. Bekaert, R. Kallel,M.-. Bouma et al., "Plasma lipoproteins in infantile visceral Leishmaniasis: deficiency of apolipoproteins A-I and A-II," Clinica Chimica Acta, vol. 184, no. 2, pp. 181-191, 1989.
21. C. S. Lal, A. Kumar, S. Kumar et al., "Hypocholesterolemia and increased triglyceride in pediatric visceral leishmaniasis," Clinica Chimica Acta, vol. 382, no. 1-2, pp. 151-153, 2007.
22. N. M. Soares, T. F. Leal, M. C. Fiúza et al., "Plasma lipoproteins in visceral leishmaniasis and their effect on Leishmaniainfected macrophages," Parasite Immunology, vol. 32, no. 4, pp. 259-266, 2010.
23. D.Rosenzweig, D. Smith, F. Opperdoes, S. Stern, R.W. Olafson, and D. Zilberstein, "Retooling Leishmania metabolism: From sand fly gut to human macrophage," The FASEB Journal, vol. 22, no. 2, pp. 590-602, 2008.
24. H. Jansen, B. Breedveld, and K. Schoonderwoerd, "Role of lipoprotein lipases in postprandial lipid metabolism," Atherosclerosis, vol. 141, no. 1, pp. S31-S34, 1998.
25. M. D. T. Carvalho, L. M. Harada, M. Gidlund, D. F. J. Ketelhuth, P. Boschcov, and E. C. R. Quintão, "Macrophages take up triacylglycerol-rich emulsions at a faster rate upon coincubation with native and modified LDL: an investigation on the role of natural chylomicrons in atherosclerosis," Journal of Cellular Biochemistry, vol. 84, no. 2, pp. 309-323, 2001.
26. M. Emi, L. L. Wu, M. A. Robertson et al., "Genotyping and sequence analysis of apolipoprotein E isoforms," Genomics, vol. 3, no. 4, pp. 373-379, 1988.
27. C. Duval, M. Muller, and S. Kersten, "PPARalpha and dyslipidemia," Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 961-971, 2007.
28. Y. I. Ahn, M. I. Kamboh, R. F. Hamman, S. A. Cole, and R. E. Ferrell, "Two DNA polymorphisms in the lipoprotein lipase gene and their associations with factors related to cardiovascular disease," Journal of Lipid Research, vol. 34, no. 3, pp. 421-428, 1993.
29. E. Socquard, A. Durlach, C. Clavel, P. Nazeyrollas, and V. Durlach, "Association of HindIII and PvuII genetic polymorphisms of lipoprotein lipase with lipid metabolism and macrovascular events in type 2 diabetic patients," Diabetes & Metabolism, vol. 32, no. 3, pp. 262-269, 2006.
30. D. P.Alonso, A. F. B. Ferreira, P. E.M.Ribolla et al., "Genotypes of themannan-binding lectin gene and susceptibility to visceral leishmaniasis and clinical complications," Journal of Infectious Diseases, vol. 195, no. 8, pp. 1212-1217, 2007.
31. T. G. Kirchgessner, J.-. Chuat, C. Heinzmann et al., "Organization of the human lipoprotein lipase gene and evolution of the lipase gene family," Proceedings of the National Academy of Sciences of theUnited States of America, vol. 86, no. 24, pp. 9647-9651, 1989.
32. K.Oka,G.T.Tkalcevic, J. Stocks, D. J. Galton, andW. V. Brown, "Nucleotide sequence of PvuII polymorphic site at the human lipoprotein lipase gene locus," Nucleic Acids Research, vol. 17,no. 16, p. 6752, 1989.
33. R. D. Santos, "III Brazilian Guidelines on Dyslipidemias and Guideline of Atherosclerosis Prevention from Atherosclerosis Department of Sociedade Brasileira de Cardiologia," Arquivos Brasileiros de Cardiologia, vol. 77, supplement 3, pp. 1-48, 2001.
34. Y. Huang, X. Q. Liu, S. C. Rail Jr., and R. W. Mahley, "Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins," The Journal of Biological Chemistry, vol. 273, no. 28, pp. 17483-17490, 1998.
35. L. Dong and K. H. Weisgraber, "Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins," Journal of Biological Chemistry, vol. 271, no. 32, pp. 19053-19057, 1996.
36. J. L. Anderson, G. J. King, T. L. Bair et al., "Association of lipoprotein lipase gene polymorphisms with coronary artery disease," Journal of the American College of Cardiology, vol. 33, no. 4, pp. 1013-1020, 1999.
37. G. Seçmeer, A. B. Cengiz, A. Gürgey et al., "Hypertriglyceridemia and decreased high-density lipoprotein could be a clue for visceral leishmaniasis," Infectious Diseases in Clinical Practice, vol. 14, no. 6, pp. 401-402, 2006.
38. A. Sapone, J. M. Peters, S. Sakai et al., "The human peroxisome proliferator-Activated receptor gene: Identification and functional characterization of two natural allelic variants," Pharmacogenetics, vol. 10, no. 4, pp. 321-333, 2000.
39. E. Rigamonti, G. Chinetti-Gbaguidi, and B. Staels, "Regulation of macrophage functions by PPAR-, PPAR-, and LXRs in mice and men," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 6, pp. 1050-1059, 2008.
40. J. Osorio y Fortéa, E. De La Llave, B. Regnault et al., "Transcriptional signatures of BALB/c mouse macrophages housing multiplying Leishmania amazonensis amastigotes," BMC Genomics, vol. 10, article 119, 2009.
41. I. Rabhi, S. Rabhi, R. Ben-Othman et al., "Transcriptomic signature of Leishmania infected mice macrophages: a metabolic point of view," PLoS Neglected Tropical Diseases, vol. 6, no. 8, Article ID e1763, 2012.
42. S. Hamdi, R. Ejghal,M. Idrissi et al., "A variant in the promoter of MBL2 is associated with protection against visceral leishmaniasis inMorocco," Infection, Genetics and Evolution, vol. 13, no. 1, pp. 162-167, 2013.
43. W. K. Eddie Ip, K. Takahashi, R. Alan Ezekowitz, and L. M. Stuart, "Mannose-binding lectin and innate immunity," Immunological Reviews, vol. 230, no. 1, pp. 9-21, 2009.
44. S. Saevarsdottir, T. Vikingsdottir, and H. Valdimarsson, "The potential role of mannan-binding lectin in the clearance of self-components including immune complexes," Scandinavian Journal of Immunology, vol. 60, no. 1-2, pp. 23-29, 2004.
45. M. Rakhshandehroo, R. Stienstra, N. J. De Wit et al., "Plasma mannose-binding lectin is stimulated by PPAR in humans," The American Journal of Physiology-Endocrinology and Metabolism, vol. 302, no. 5, pp. E595-E602, 2012.
46. M. Panadero, C. Bocos, and E. Herrera, "Relationship between lipoprotein lipase and peroxisome proliferator-Activated receptor- expression in rat liver during development," Journal of Physiology and Biochemistry, vol. 62, no. 3, pp. 189-198, 2006.